(JREM) JPMorgan s (Ireland) ICAV - Overview
Etf: Equity, Emerging, ESG, Index, Acc
| Risk 5d forecast | |
|---|---|
| Volatility | 14.8% |
| Relative Tail Risk | -4.06% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.10 |
| Alpha | 18.84 |
| Character TTM | |
|---|---|
| Beta | 0.224 |
| Beta Downside | 0.484 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.29% |
| CAGR/Max DD | 0.72 |
Description: JREM JPMorgan s (Ireland) ICAV December 30, 2025
The JPMorgan ETFs (Ireland) ICAV Global Emerging Markets Research Enhanced Index Equity (ESG) UCITS ETF (ticker JREM) tracks the Morningstar Emerging Markets Total Market Index (Net Return, USD). It is domiciled in Germany, listed on XETRA, and classified as a Global Emerging Markets Equity fund.
Key quantitative traits (as of the latest public filings) include an expense ratio of roughly 0.20% and assets under management estimated at ≈ $2.5 billion. The fund’s top ten holdings are heavily weighted toward Chinese technology and consumer firms, Indian financials, and Brazilian commodities producers, giving it a sector profile of ~45% technology, 25% financials, and 15% materials. The ESG overlay excludes companies failing JPMorgan’s sustainability screens, resulting in a carbon intensity about 30% lower than the broader EM market.
Fund performance is driven by macro-factors such as China’s GDP growth trajectory, commodity price cycles, and the pace of monetary tightening in advanced economies, which affect capital flows into emerging-market equities. A recent KPI worth monitoring is the fund’s net asset flow: a net inflow of ≈ $150 million in Q3 2024, indicating continued investor appetite despite elevated valuation levels.
For a deeper dive into how JREM’s ESG tilt impacts risk-adjusted returns, you might explore the analytics on ValueRay to see comparative factor breakdowns.
What is the price of JREM shares?
Over the past week, the price has changed by +1.15%, over one month by +4.17%, over three months by +9.14% and over the past year by +26.34%.
Is JREM a buy, sell or hold?
What are the forecasts/targets for the JREM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 40.9 | 7.2% |
JREM Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.25b EUR (1.25b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.25b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.25b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.74% (E(1.25b)/V(1.25b) * Re(6.74%) + (debt-free company))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)